Versartis Reports Confirmatory Top-Line Two-Year Data from Ongoing Extension Study of Somavaratan in GHD Children
Safe and well tolerated over two years Height velocity (HV) in second year comparable to published US rhGH daily dosing data; further confirms Phase 3 dose and schedule Extremely high rate of adherence to dosing schedule in Extension Study (18 months of at …